Global DrugEluting Balloon Market, by Product Type (Coronary Drug Eluting Balloon,Peripheral Drug Eluting Balloon, and Others), by End User (Hospitals, CATHLaboratories, Ambulatory Surgery Centers, and Others), and by Region (NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa) wasvalued at US$ 420.0 Million in 2017, and is projected to exhibit a CAGR of 8.1%over the forecast period (2018 – 2026).
Launch of novel drug elutingballoons by market players to augment the market growth Key players in the marketare focused on launching novel drug eluting balloons in order to treat coronaryartery disease and other diseases and address the critical unmet needs ofpatients. For instance, in October 2014, C.R. Bard’s received U.S. Food andDrug Administration (FDA) approval for Lutonix 035 drug eluting balloon that isused in popliteal arteries in upper legs. Similarly, in January 2015, Medtronicreceived clearance from the U.S. FDA for In.Pact Admiral Drug eluting balloonthat is used in the superficial femoral and popliteal arteries in upper legs,thereby providing new opportunities for Medtronic and C.R. Bard’s in offeringeffective treatment options among the fastest growing markets worldwide.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2459
In July 2017, Spectranetics Corp.received pre-market approval (PMA) from U.S. FDA for Stellarex drug coatedballoon that is used for restoration and maintenance of blood flow to thesuperficial femoral and popliteal arteries in patients with peripheral arterialdisease.
Browse 35 Market Data Tables and28 Figures spread through 168 Pages and in-depth TOC on ‘Drug Eluting BalloonMarket’- Global Forecast to 2026, by Product Type (Coronary Drug ElutingBalloon, Peripheral Drug Eluting Balloon, and Others), by End User (Hospitals,CATH Laboratories, Ambulatory Surgery Centers, and Others), and by Region(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Key players in the market arefocused on adopting strategies such as mergers and acquisitions to enhancetheir product portfolio. For instance, in November 2014, Medtronic, Inc.acquired Covidien, plc, a company involved in developing and manufacturing a range of medical devicesand supplies, including laproscopic surgery, electrosurgery, and vasculartherapies. Covidien sells its products in over 150 countries.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/drug-eluting-balloon-market-2459
Key Takeaways of the Drug ElutingBalloon Market:
The global drug eluting balloonmarket is expected to exhibit a CAGR of 8.1% over the forecast period, owing toincreasing prevalence of coronary artery diseases, diabetes, and obesity,increased use of tobacco and smoking, and increasing geriatric population proneto cardiovascular diseases
Among product type, theperipheral drug eluting balloon segment held a dominant position in the drugeluting balloon market in 2018. This is owing to increasing use of drug elutingballoon in the treatment of peripheral artery disease as the treatment showsimproved patency rate as compared to standard Percutaneous TransluminalAngioplasty (PTA) balloons.
Among end user, hospitals and ambulatoryservice centers segment held a dominant position in the drug eluting balloonmarket in 2018, owing to high adoption rate of the devices in hospitals andambulatory service centers
Key players operating in theglobal drug eluting balloon market include, Medtronic, Becton, Dickinson andCompany (BD), Boston Scientific Corporation, Cook Medical, B. Braun MelsungenAG, Koninklijke Philips N.V., Opto Circuits (India) Limited, TerumoCorporation, Surmodics, Inc., and Biotronik
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2459
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
